이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Intercept Pharmaceuticals 관리

관리 기준 확인 3/4

Intercept Pharmaceuticals' CEO는 Jerry Durso, Jan2021 에 임명되었습니다 의 임기는 2.42 년입니다. 총 연간 보상은 $ 4.46M, 16% 로 구성됩니다. 16% 급여 및 84% 보너스(회사 주식 및 옵션 포함). 는 MX$ 10.62M 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 10.62M. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 9.1 년입니다.

주요 정보

Jerry Durso

최고 경영자

US$4.5m

총 보상

CEO 급여 비율	16.0%
CEO 임기	2.4yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	9.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jerry Durso 의 보수는 Intercept Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$173m
Dec 31 2022	US$4m	US$715k	-US$175m
Sep 30 2022	n/a	n/a	-US$202m
Jun 30 2022	n/a	n/a	-US$115m
Mar 31 2022	n/a	n/a	-US$120m
Dec 31 2021	US$8m	US$691k	-US$136m
Sep 30 2021	n/a	n/a	-US$144m
Jun 30 2021	n/a	n/a	-US$193m
Mar 31 2021	n/a	n/a	-US$231m
Dec 31 2020	US$4m	US$600k	-US$273m
Sep 30 2020	n/a	n/a	-US$321m
Jun 30 2020	n/a	n/a	-US$339m
Mar 31 2020	n/a	n/a	-US$347m
Dec 31 2019	US$4m	US$573k	-US$345m
Sep 30 2019	n/a	n/a	-US$335m
Jun 30 2019	n/a	n/a	-US$314m
Mar 31 2019	n/a	n/a	-US$318m
Dec 31 2018	US$3m	US$541k	-US$309m
Sep 30 2018	n/a	n/a	-US$333m
Jun 30 2018	n/a	n/a	-US$341m
Mar 31 2018	n/a	n/a	-US$352m
Dec 31 2017	US$4m	US$441k	-US$360m

보상 대 시장: Jerry 의 총 보상 ($USD 4.46M )은 MX 시장( $USD 256.93K ).

보상과 수익: Jerry 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jerry Durso (55 yo)

2.4yrs

테뉴어

US$4,455,463

보상

Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jerome Durso	President	2.4yrs	US$4.46m	0.12% $ 10.6m
Andrew Saik	Chief Financial Officer	2yrs	US$1.39m	0.036% $ 3.1m
Jared Freedberg	General Counsel	2.3yrs	US$1.31m	0.14% $ 11.9m
Linda Richardson	Executive VP & Chief Commercial Officer	2.3yrs	US$1.34m	0.040% $ 3.4m
M. Berrey	President of Research & Development and Chief Medical Officer	2yrs	US$1.61m	0.054% $ 4.6m
Rocco Venezia	Chief Accounting Officer & Treasurer	2.3yrs	US$856.23k	0.061% $ 5.2m
Nareg Sagherian	Executive Director of Global Investor Relations	1.5yrs	데이터 없음	데이터 없음
David Ford	Chief Human Resources Officer	6.1yrs	US$1.91m	0.060% $ 5.1m
Mark Pruzanski	Founder	2.4yrs	US$6.43m	1.48% $ 126.8m
Paul Nitschmann	Senior Vice President of Regulatory Affairs	no data	데이터 없음	데이터 없음
Kathleen Munster	Chief Quality Officer & SVP of Technical Operations	less than a year	데이터 없음	데이터 없음
Michael Blash	Senior Vice President of Corporate Affairs	less than a year	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: ICPT * 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jerome Durso	President	2.1yrs	US$4.46m	0.12% $ 10.6m
Mark Pruzanski	Founder	21.4yrs	US$6.43m	1.48% $ 126.8m
Daniel Bradbury	Independent Director	6.9yrs	US$327.39k	0.056% $ 4.8m
Glenn Sblendorio	Independent Director	9.3yrs	US$332.39k	0.056% $ 4.8m
Luca Benatti	Independent Director	8.9yrs	US$327.39k	0.061% $ 5.2m
Srinivas Akkaraju	Independent Director	10.7yrs	US$317.39k	0.091% $ 7.8m
Gino Santini	Lead Independent Director	7.6yrs	US$337.39k	0.057% $ 4.8m
Paolo Fundaro	Independent Chairman of the Board	17.1yrs	US$342.39k	0.086% $ 7.3m
Alan Hofmann	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Scott Friedman	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Massimo Pinzani	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Aldo Roda	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음

9.1yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: ICPT * 의 이사회는 경험(평균 재직 기간 9.1 년)으로 간주됩니다.

Intercept Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Recent updates

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast breakeven date moved forward to 2022

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령